The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide
Open accessAbstract
Objective: Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that is usually treated with an extended course of intravenous (IV) cyclophosphamide (CYC). Given the side effects of this regimen, we evaluated the efficacy and the toxicity of a course of low‐dose IV CYC prescribed as a remission‐inducing treatment, followed by azathioprine (AZA) as a remission‐maintaining treatment. Methods: In this multicenter, prospective clinical trial (the Euro‐Lupus Nephritis Trial [ELNT]), we randomly assigned 90 SLE patients with proliferative glomerulonephritis to a high‐dose IV CYC regimen (6 monthly pulses and 2 quarterly pulses; doses increased according to the white blood cell count nadir) or a low‐dose IV CYC regimen (6 fortnightly pulses at a fixed dose of 500 mg), each of which was followed by AZA. Intent‐to‐treat analyses were performed. Results: Followup continued for a median of 41.3 months in the low‐dose group and 41 months in the high‐dose group. Sixteen percent of those in the low‐dose group and 20% of those in the high‐dose group experienced treatment failure (not statistically significant by Kaplan‐Meier analysis). Levels of serum creatinine, albumin, C3, 24‐hour urinary protein, and the disease activity scores significantly improved in both groups during the first year of followup. Renal remission was achieved in 71% of the low‐dose group and 54% of the high‐dose group (not statistically significant). Renal flares were noted in 27% of the low‐dose group and 29% of the high‐dose group. Although episodes of severe infection were more than twice as frequent in the high‐dose group, the difference was not statistically significant. Conclusion: The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission‐inducing regimen of low‐dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with a high‐dose regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Grinyo, J. M., GROTH, C. G., Pichlmayr, R., Sadek, S., Vanrenterghem, Y. F. C., Behrend, M., Luck, R. P., Moreso, F., Peeters, J. A. G., Rodicio, J. L., et al. (1995) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 974
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
European Mycophenolate Mofetil Cooperative Study Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92534-1 · Cited by 927
Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 823
A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., et al. (1998) · Transplantation · doi:10.1097/00007890-199808270-00016 · Cited by 615
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
(2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440513 · Cited by 539
Boumpas, D. T., Austin, H. A., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Balow, J. E. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00003 · Cited by 500
Illei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 492
Treasure, T., & MacRae, K. D. (1998) · BMJ · doi:10.1136/bmj.317.7155.362 · Cited by 344
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Vitali, C., Bencivelli, W., Isenberg, D. A., Smolen, J. S., Snaith, M. L., Sciuto, M. E., Neri, R., & Bombardieri, S. (1992) · PubMed · Cited by 317
Treatment of lupus nephritis: A meta-analysis of clinical trials
Bansal, V. K., & Beto, J. A. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90029-9 · Cited by 162
Haga, H. J., D’Cruz, D. P., Asherson, R. A., & Hughes, G. R. (1992) · Annals of the Rheumatic Diseases · doi:10.1136/ard.51.7.885 · Cited by 53
Self-citationStaring into the abyss: walking the nuclear tightrope in south Asia
Bhutta, Z. A. (1998) · BMJ · doi:10.1136/bmj.317.7155.363 · Cited by 8
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Metadata
- Authors
- Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., Galeazzi, M., Gül, A., Levy, Y., Petera, P., Popovic, R., Petrovic, R., Sinico, R. A., Cattaneo, R., Font, J., Depresseux, G., Cosyns, J., & Cervera, R.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-08
- Volume
- 46
- Issue
- 8
- Pages
- 2121-2131
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2096194879
- Cited by
- 1,077
- References
- 17
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.